The Government will distribute almost 40 million euros to the Autonomous Communities to Personalized Precision Medicine centered on the patient as part of the transfers planned by the 5P Plan Ministry of Health. Its objective is, as the minister of the branch has highlighted, Carolina Darias, “that all patients live where they live or go to the hospital center they go to receive the same care and therefore have access to the genetic determinations that are necessary for the best diagnosis, treatment or their disease, deploying all the necessary infrastructure for this” . This was revealed during his speech after the Minister council.
As has been recalled, Health leads and promotes together with the CCs. AA. and the ISCIII, in addition to the Network of Health Technology Assessment Agencies, the aforementioned project.
The approval of the authorization for the aforementioned distribution of funds, as indicated by the person in charge “comes from an agreement with Pharmaindustry intended to finance this sustainability program of the National Health System (SNS). “Specifically, to the consolidation of “a more innovative, safe, efficient and precise medicine”, he underlined.
The materialization of this “à la carte” medicine, as Darias has described, will see part of its national plan with this capital transfer. Its destination will be the technological improvements for the acquisition of equipment, such as laboratories to make the genetic sequencing, as exemplified by the minister. Also “information systems that allow the exploitation of data analytics and training for health professionals”. “These are increasingly advanced techniques, which are now in the hands of certain hospitals; we want to spread it throughout the country”, she pointed out.
Specific investment objectives
The reference of the meeting of portfolio owners of the Executive sheds more light on these aspects. In the field of training, the investment must assume that this “must reach not only the professionals who apply the techniques but also those who request them”. Similarly, mention is made of the acquisition of technology and equipment cited above, “including those related to sequencing to carry out complex genomic determinations and the determination of diagnostic, prognostic or predictive biomarkers of response to treatment in various pathologies”.
It also abounds in the attainment of resources and infrastructures necessary for the storage, processing and analysis of data derived from genomic tests “having secure servers and with the operational capacity to store the genetic data associated with each patient”. At this point, it is considered necessary to “invest in analysis software with tools that allow information to be automatically extracted from external scientific sources, linking it to genetic markers associated with diseases and available drugs to improve patient care.”
Among its objectives is to promote regional commissions for the incorporation of these advances
Ultimately, the amount validated by the Council of Ministers will have the task of promoting regional commissions for the incorporation of these disruptive advances, so that this is “a very lively process”, according to Darias. In this regard, the reference speaks of the creation and consolidation of these regional genetics commissions “as a coordinating body on genetics in each CC. AA., whose functions and composition will be regulated by their health authorities”.
Without prejudice to the above measures, the reference reveals that the amount distributed may be invested in the implementation of the measures agreed within the Pharmaceutical Provision Advisory Committee (CPAF) related to the genomics portfolio and the corresponding catalogue. Likewise, it may also be invested in the implementation of the measures agreed within the Permanent Pharmacy Commissionwithin the scope of its functions.
As the minister has detailed, genetic tests constitute a tool of great value for approaching and improving the prognosis —along with its social perspective— of the diseases with high health impactsuch as rare diseases. Also “for the indication of the follow-up of optimal pharmacological treatmentsince more and more frequently we think of specific biomarkers that contribute to providing greater safety and efficiency in the use of medicines”, he explained.
For this reason, Darias has taken advantage of his speech to schedule the roadmap for this 5P Plan, which consists of three phases, whose starting point took place at the end of 2021, when the Interterritorial Council held in December approved the update of the SNS Common Portfolio of Services in genetics. “It will be effective when the corresponding ministerial order is published; we are working on it and this update will be published shortly”, he announced. This update includes general aspects of patient care but also that of their relatives, including genetic and genomic analyses”, added the person in charge.
The oncohematology area will be the first beneficiary of this plan at the beginning of 2023
Secondly, once the portfolio has been updated, Health foresees the specification of the same in the catalog of benefits to give the right to access this type of treatment throughout the national territory. In this sense, Darias has outlined that “we are working on 18 specific thematic areas. The first to see the light will be the oncohematology area at the beginning of the year 2023″.
The third phase would correspond to the organizational part of the model “to implement it in a coordinated and cohesive manner in all the CCs. AA., objective of the transfer of funds approved in the Council of Ministers.